Jeffrey J. Fessler

Jeffrey Fessler is a partner in the Corporate Practice Group in the firm's New York office. Jeffrey is Leader of the firm’s Capital Markets and Public Companies team, as well as the firm’s Life Sciences Team.

Areas of Practice

Jeffrey is principally engaged in the practice of corporate and securities law. His practice is focused on the representation of public and private companies, principally in the biotechnology industry. Jeffrey has extensive experience representing investment banks and companies in public offerings and private placements as well as exchange listings and compliance. In addition, Jeffrey has been involved in a wide variety of corporate transactions, including mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings, as well as securities disclosure issues and corporate governance. In addition to the biotechnology industry, Jeffrey also represents companies in a variety of industries, including technology, telecommunications, broadcasting and healthcare.

Experience

Recent Representative Transactions

• Represented BioXcel Therapeutics, Inc. in its $60 million initial public offering
• Represented Aridis Pharmaceuticals, Inc. in its $26 million initial public offering
• Represented Synergy Pharmaceuticals, Inc. in its $125 million follow-on public offering
• Represented Synergy Pharmaceuticals, Inc. in its $200 million Convertible Note Rule 144A offering
• Represented Synergy Pharmaceuticals, Inc. in its $17.25 million public offering and uplisting to Nasdaq, as well as a subsequent $51 million public offering
• Represented Trovagene, Inc. in its $9.2 million public offering and uplisting to Nasdaq
• Represented ContraVir Pharmaceuticals in its $7 million follow-on offering, as well as its subsequent $12 million follow-on offering
• Represented Northwest Biopharmaceuticals, Inc. in its $12 million public offering and uplisting to Nasdaq
• Represented Sorrento Therapeutics, Inc. in its $34.6 million public offering and uplisting to Nasdaq, as well as a subsequent $28.8 million public offering
• Represented an underwriter in a $10.4 million public offering and Nasdaq uplisting for a cancer drug development company
  

Honors

Attorney of the Year, SmartCEO, 2014

Articles

Corporate and Securities Law Blog Posts

• "Delaware Court of Chancery Holds that a Stockholder’s Disagreement with a Board’s Business Judgment and Intent to Pursue a Proxy Contest is Not a “Proper Purpose” for a Section 220 Demand," November 19, 2019
• "SEC Looks to Modernize Disclosure Approach," September 18, 2019 
• "SEC Issues New Guidance on Diversity Disclosure Requirements," February 11, 2019 
• "SEC Expands the Definition of 'Smaller Reporting Company'," July 12, 2018
• "New Law Requires SEC to Expand Regulation A+ To Exchange Act Reporting Companies," June 19, 2018 
• "SEC Approves New Audit Reporting Standard Requiring Auditors to Disclose More Detailed Information Learned During the Audit," November 2, 2017 

Media Mentions

Memberships

Certified Public Accountant (New Jersey)